All In Biotech

Drug Trial Radar · NCT01897987

Follow-up Safety and Efficacy Evaluation on Subjects Who Completed PNEUMOSTEM® Phase-II Clinical Trial

Follow-up Safety and Efficacy Evaluation on Subjects Who Completed the Initial Stage of PNEUMOSTEM® Phase-II Clinical Trial

Last checked: Nov 20, 2026Latest source record: Aug 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

62

Actual

Start

Jan 2014

Primary completion

Mar 2020

Study completion Mar 2020

Sponsor

Lead sponsor
Medipost Co Ltd.Industry
Sponsor type
Industry
First posted
Jul 12, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 7 months, up to 7 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a follow-up study to investigate the long-term safety and efficacy of PNEUMOSTEM® versus placebo, for the treatment of BPD in premature infants. Subjects who participated in and completed the initial stage of the Phase II trial (NCT01828957) will be followed-up until 60 months of corrected age.

Conditions

  • Bronchopulmonary Dysplasia

Interventions

  • Pneumostem®Biological

  • normal salineBiological

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Respiratory outcome: readmission rate and duration of the hospital stay due to respiratory infectionTime frame: 6, 12, 18, 24, 36, 48, and 60 months, corrected age

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.